August 19, 2011 — NeoStem Inc., an international biopharmaceutical company, reported progress toward commencement of a Phase II clinical trial for AMR-001 for the treatment of acute myocardial infarction. The stem cell product is from Amorcyte Inc., a NeoStem subsidiary.

August 18, 2011 – At the 39th Annual AHRA Meeting and Exposition, Fujifilm Medical Systems U.S.A. announced the commercial availability of Synapse Mobility, a zero-footprint application that enables access to Fujifilm's suite of Synapse products from hand-held mobile devices, as well as Macintosh- or Windows-based PCs. Using the Web browser of their choice, radiologists and referring physicians can now have on-the-go access to the images and information stored in Synapse PACS and Synapse RIS, increasing accessibility to patient information and improving workflow.

August 18, 2011 - A new KLAS report, "Positron Emission Tomography (PET)/Computed Tomography (CT) 2011-New Technologies in Focus," measures the innovative pairing of nuclear medicine scan technologies and reviews of the top three vendors in the market space: GE Healthcare, Philips and Siemens.


August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial infarction or stroke. The results were from a sub-analysis of patients from the TRITON-TIMI 38 study. This was compared to treatment with clopidogrel (trade name Plavix - 8.3 percent vs. 11 percent, respectively, p<0.0001). This corresponds to a 2.7 percent absolute risk reduction for patients treated with prasugrel.

August 17, 2011 — A scientist at the Gladstone Institutes has discovered how a gene known as SIRT3 contributes to a suite of health problems, offering new insight into how to combat these potentially fatal conditions.

August 17, 2011 — The Society of Cardiovascular Computed Tomography (SCCT) announced the election of James K. Min, M.D., FSCCT, as its new president and John R. Lesser, M.D., FSCCT, as president-elect of the organization. Jeffrey J. Carr, M.D., FSCCT, is the vice president and Ricardo C. Cury, M.D. is joining the executive committee as treasurer. The announcement was made official at the sixth annual scientific meeting, recently held in Denver, Colo.

August 17, 2011 — OrbusNeich announced its Genous stent showed no significant difference in target vessel failure (TVF) rate at two years from the Taxus Liberte paclitaxel-eluting stent in patients with de novo coronary artery lesions at high risk for restenosis. The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now